←
Telo Genomics Corp174 posts
Telo Genomics Corp avatar

Telo Genomics Corp

@TeloGenomics

Genomic Imaging for Precision Medicine. TSX.V TELO | OTCQB:TDSGF | FSE:3D0

◷ Joined September 2016▧ 99 Photos and videos
Telo Genomics Corp avatar
Telo Genomics Corp@TeloGenomics·21 Jan 2025

TeloView assays have been validated as binary risk classifiers to provide an actionable test result that supports the decision making of oncologists. Telo Genomics’ lead assay, TeloViewSMM, fills a critical unmet need by risk stratifying smoldering myeloma patients.

Post attachment
Telo Genomics Corp avatar
Telo Genomics Corp@TeloGenomics·15 Jan 2025

2024 was a significant year for expanding the evidence of TeloView utility. Telo Genomics completed the clinical validation of its first assay, TeloViewSMM for smoldering multiple myeloma, with a publication in American Journal of Hematology.

Post attachment
Telo Genomics Corp avatar
Telo Genomics Corp@TeloGenomics·12 Nov 2024

Myeloma Canada’s 15th Scientific Roundtable had the absolute highest quality of talks in myeloma immunotherapy, featuring Vincent Rajkumar, Annette Hay, Nizar Bahlis, Tom Martin. Telo Genomics’ CTO spoke about TeloView prognostics product offering for multiple myeloma.

Post attachmentPost attachment
Telo Genomics Corp avatar
Telo Genomics Corp@TeloGenomics·29 Oct 2024

Telo Genomics has participated in the 21st International Myeloma Society Annual Meeting in Rio De Janeiro. We thank all the hematologists, academics and industry for their engagement at our poster session and booth. #IMS24

Post attachmentPost attachment
Telo Genomics Corp avatar
Telo Genomics Corp@TeloGenomics·17 Oct 2024

Telo Genomics is validating 2 MRD applications in an active clinical trial, each with their own value propositions. The two MRD assays join the suite of Telo Genomics product offerings supporting #myeloma hematologists along the entire disease spectrum.

Post attachment